[go: up one dir, main page]

CL2008002542A1 - Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis. - Google Patents

Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis.

Info

Publication number
CL2008002542A1
CL2008002542A1 CL2008002542A CL2008002542A CL2008002542A1 CL 2008002542 A1 CL2008002542 A1 CL 2008002542A1 CL 2008002542 A CL2008002542 A CL 2008002542A CL 2008002542 A CL2008002542 A CL 2008002542A CL 2008002542 A1 CL2008002542 A1 CL 2008002542A1
Authority
CL
Chile
Prior art keywords
compounds
pharmaceutical composition
amyloidosis
amyloid
dementia
Prior art date
Application number
CL2008002542A
Other languages
English (en)
Inventor
Teiji Kimura
Noritaka Kitazawa
Toshihiko Kaneko
Nobuaki Sato
Koki Kawano
Koichi Ito
Mamoru Takaishi
Takeo Sasaki
Yu Yoshida
Toshiyuki Uemura
Takashi Doko
Daisuke Shinmyo
Daiju Hasegawa
Takehiko Miyagawa
Hiroaki Hagiwara
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of CL2008002542A1 publication Critical patent/CL2008002542A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

COMPUESTOS REPRESENTADOSPOR LA FÓRMULA (I-1), O SUS SALES FARMACOLÓGICAMENTE ACEPTABLES, DONDE X1 Y HET SON COMO SE DEFINE EN LAS REIVINDICACIONES. COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DICHOS COMPUESTOS O SUS SALES FARMACOLÓGICAMENTEACEPTABLES, EN FORMA DE UN INGREDIENTEACTIVO. USO DE DICHA COMPOSICIÓN FARMACÉUTICA PARA PREVENIR O TRATAR UNA ENFERMEDAD CAUSADA POR AMILOIDE-B, TAL COMO ENFERMEDADDE ALZHEIMER, DEMENCIA, SÍNDROME DE DOWN O AMILOIDOSIS.
CL2008002542A 2007-08-31 2008-08-28 Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis. CL2008002542A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007225045 2007-08-31
JP2008020009 2008-01-31
JP2008123057 2008-05-09

Publications (1)

Publication Number Publication Date
CL2008002542A1 true CL2008002542A1 (es) 2009-01-02

Family

ID=40387302

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002542A CL2008002542A1 (es) 2007-08-31 2008-08-28 Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis.

Country Status (19)

Country Link
US (1) US9453000B2 (es)
EP (2) EP2181992B8 (es)
JP (1) JP5433418B2 (es)
KR (1) KR20100055456A (es)
CN (1) CN101815713B (es)
AR (1) AR068121A1 (es)
AU (1) AU2008292390B2 (es)
BR (1) BRPI0815773A2 (es)
CA (1) CA2694401C (es)
CL (1) CL2008002542A1 (es)
ES (1) ES2529648T3 (es)
IL (1) IL203778A (es)
MX (1) MX2010002098A (es)
MY (1) MY150507A (es)
NZ (1) NZ583515A (es)
PE (1) PE20090674A1 (es)
TW (1) TW200916469A (es)
WO (1) WO2009028588A1 (es)
ZA (1) ZA201000474B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US20090124651A1 (en) * 2007-08-31 2009-05-14 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
EP2181992B8 (en) 2007-08-31 2013-06-26 Eisai R&D Management Co., Ltd. Polycyclic compound
EP2324009A1 (en) * 2008-08-27 2011-05-25 Eisai R&D Management Co., Ltd. Process for preparing certain cinnamide compounds
AU2009316557B2 (en) 2008-11-19 2015-08-27 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl) benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
JP2012051805A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd テトラヒドロトリアゾロピリジン誘導体の製造方法
CN102333777B (zh) 2009-02-26 2014-06-25 卫材R&D管理有限公司 含氮的稠合杂环化合物及其作为β淀粉样蛋白生成抑制剂的用途
WO2010098490A1 (en) * 2009-02-26 2010-09-02 Eisai R&D Management Co., Ltd. Salt of tetrahydrotriazolopyridine derivative and crystal thereof
JP2012121809A (ja) * 2009-02-26 2012-06-28 Eisai R & D Management Co Ltd 多環式化合物の製造法およびその中間体
KR20120032479A (ko) * 2009-05-11 2012-04-05 더 리전트 오브 더 유니버시티 오브 캘리포니아 유비퀴틴화된 단백질 수준을 감소시키는 방법
BRPI1014793A2 (pt) * 2009-05-11 2016-04-05 Envivo Pharmaceuticals Inc tratamento de distúrbios de cognição com determinados receptores de ácido alfa-7-nicotínico em combinação com inibidores de acetil-colinesterase
CN102574776A (zh) * 2009-07-31 2012-07-11 桑多斯股份公司 ω-氨基-烷酰胺和ω-氨基-烷硫酰胺的制备方法及该方法的中间体
WO2011086098A1 (en) * 2010-01-15 2011-07-21 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Novel substituted bicyclic triazole derivatives as gamma secretase modulators
CA2799744C (en) 2010-05-17 2020-01-28 Envivo Pharmaceuticals, Inc. A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
US9585877B2 (en) 2012-05-08 2017-03-07 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
SG11201407051XA (en) 2012-05-16 2014-11-27 Janssen Pharmaceuticals Inc Substituted 3, 4 - dihydro - 2h - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) alzheimer's disease
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
CA2889249C (en) 2012-12-20 2021-02-16 Francois Paul Bischoff Tricyclic 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma secretase modulators
EP2945944B1 (en) 2013-01-17 2016-11-09 Janssen Pharmaceutica, N.V. Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
US10372396B2 (en) * 2013-02-21 2019-08-06 Lenovo ( Singapore) Pte. Ltd. Discovery and connection to wireless displays
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
EP3253755B1 (en) 2015-02-03 2020-08-26 Pfizer Inc Novel cyclopropabenzofuranyl pyridopyrazinediones
US11020403B2 (en) * 2017-06-02 2021-06-01 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
KR20200118005A (ko) * 2018-02-05 2020-10-14 위니베르시떼 드 스트라스부르 통증 치료용 화합물 및 조성물
US12290510B2 (en) 2019-02-07 2025-05-06 Riesner Verwaltungs Gmbh Polyvalent derivatives of emoxypine
EP4634167A1 (en) * 2022-12-15 2025-10-22 Sitryx Therapeutics Limited Substituted pyridines for use in treating or preventing inflammatory diseases or diseases associated with an undesirable immune response
CN118459425B (zh) * 2024-04-29 2025-11-14 南通华祥医药科技有限公司 一种吡咯烷-1-胺-二盐酸盐的制备方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1101156A (en) 1965-09-22 1968-01-31 Hickson & Welch Ltd Triazole derivatives and their use as optical whitening agents
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
FR2314731A1 (fr) 1975-06-19 1977-01-14 Nelson Res & Dev Azacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients
US4508718A (en) 1984-01-16 1985-04-02 Warner-Lambert Company Cardiotonic and antihypertensive oxadiazinone compounds
ES2061432T3 (es) 1985-10-09 1994-12-16 Shell Int Research Nuevas amidas de acido acrilico.
US4783463A (en) 1985-10-23 1988-11-08 Rorer Pharmaceutical Corporation Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure
DE3541716A1 (de) 1985-11-26 1987-05-27 Celamerck Gmbh & Co Kg Neue acrylsaeureamide
FI91754C (fi) 1986-12-02 1994-08-10 Tanabe Seiyaku Co Analogiamenetelmä lääkeaineena käyttökelpoisen imidatsolijohdannaisen valmistamiseksi
FI902321A7 (fi) 1989-05-19 1990-11-20 Eisai Co Ltd Buteenihappojohdannaiset
JPH03206042A (ja) * 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
EP0468054B1 (en) 1990-02-08 1997-05-28 Eisai Co., Ltd. Benzenesulfonamide derivative
AU680870B2 (en) 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
AU3577995A (en) 1994-10-04 1996-04-26 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
JPH08283219A (ja) 1995-04-07 1996-10-29 Eisai Co Ltd アラルキルアミノアルキルアミド誘導体
US5804577A (en) 1995-09-12 1998-09-08 Hoffmann-La Roche Inc. Cephalosporin derivatives
WO1997014417A1 (en) 1995-10-19 1997-04-24 Merck & Co., Inc. Fibrinogen receptor antagonists
KR20000010918A (ko) 1996-05-10 2000-02-25 게리 엘. 윌콕스 카르볼린 유도체
CN1238688A (zh) 1996-07-22 1999-12-15 孟山都公司 硫羟磺酰胺金属蛋白酶抑制剂
US5672612A (en) 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
WO1998024785A1 (en) 1996-12-02 1998-06-11 Fujisawa Pharmaceutical Co., Ltd. Indole-urea derivatives with 5-ht antagonist properties
AU6520098A (en) 1997-03-31 1998-10-22 Takeda Chemical Industries Ltd. Azole compounds, their production and their use
JP3108997B2 (ja) 1997-03-31 2000-11-13 武田薬品工業株式会社 アゾール化合物、その製造法および用途
PL336304A1 (en) 1997-04-16 2000-06-19 Abbott Lab 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their application as adenosine kinase inhibitors
TW379224B (en) 1997-12-02 2000-01-11 Fujisawa Pharmaceutical Co Urea derivatives
CA2317008C (en) 1997-12-31 2009-01-20 The University Of Kansas Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
GB9816984D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US6048678A (en) * 1998-12-28 2000-04-11 Eastman Kodak Company Protective overcoat coating compositions
US6235728B1 (en) 1999-02-19 2001-05-22 Bristol-Myers Squibb Company Water-soluble prodrugs of azole compounds
WO2000050391A1 (en) 1999-02-26 2000-08-31 Merck & Co., Inc. Novel sulfonamide compounds and uses thereof
AU2899400A (en) 1999-03-04 2000-09-21 Nortran Pharmaceuticals Inc. Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics
AU2001241128A1 (en) 2000-03-14 2001-09-24 Fujisawa Pharmaceutical Co. Ltd. Novel amide compounds
US20010051642A1 (en) 2000-04-17 2001-12-13 Kyunghye Ahn Method for treating Alzheimer's disease
WO2001081312A2 (en) 2000-04-24 2001-11-01 Merck Frosst Canada & Co. Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
KR100515549B1 (ko) 2000-12-04 2005-09-20 에프. 호프만-라 로슈 아게 글루타메이트 수용체 길항제로서의 페닐에테닐 또는페닐에티닐 유도체
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
EP1427412A1 (en) 2001-09-13 2004-06-16 Boehringer Ingelheim Pharmaceuticals Inc. Methods of treating cytokine mediated diseases
MXPA04002404A (es) 2001-09-14 2004-05-31 Novo Nordisk As Ligandos novedosos para los sitios hisb10zn2+ del hexamero de insulina en estado r.
RU2004118719A (ru) 2001-11-22 2005-03-27 Оно Фармасьютикал Ко., Лтд. (Jp) Производные пиперидин-2-она и фармацевтические композиции, содержащие такие соединения в качестве активного ингредиента
MXPA04005427A (es) 2001-12-10 2005-04-19 Amgen Inc Ligandos de receptor vainilloide y su uso en tratamientos.
HUP0500173A3 (en) 2001-12-20 2009-03-30 Bristol Myers Squibb Co Alpha-sulphonamido-acetamide derivatives as beta-amyloid inhibitors and pharmaceutical compositions containing them
JP2003206280A (ja) 2001-12-28 2003-07-22 Takeda Chem Ind Ltd ビアリール化合物およびその用途
EP1509505A2 (en) 2002-01-23 2005-03-02 Arena Pharmaceuticals, Inc. SMALL MOLECULE MODULATORS OF THE 5−HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO
AU2003225668A1 (en) 2002-03-01 2003-09-16 Pintex Pharmaceutical, Inc. Pin1-modulating compounds and methods of use thereof
GB0207436D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
TW200307667A (en) 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
PL375552A1 (en) 2002-05-22 2005-11-28 Amgen Inc. Vanilloid receptor ligands and their medical applications
PT1511710E (pt) 2002-05-31 2014-02-26 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
US7459476B2 (en) 2002-06-27 2008-12-02 Elan Pharmaceuticals, Inc. Methods for treating Alzheimer's disease using hydroxyethylene compounds containing a heterocyclic amide bond isostere
WO2004007455A1 (de) 2002-07-12 2004-01-22 Aventis Pharma Deutschland Gmbh Heterozyklisch substituierte benzoylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US6900354B2 (en) 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
EP1594847A2 (en) 2003-02-12 2005-11-16 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
CA2521095A1 (en) 2003-04-01 2004-10-21 Plus Chemicals, B.V. Amorphous simvastatin calcium and methods for the preparation thereof
CN1787822A (zh) * 2003-05-14 2006-06-14 托里派因斯疗法公司 化合物及其在调节淀粉样蛋白β中的用途
MXPA05012281A (es) 2003-05-14 2006-05-19 Torreypines Therapeutics Inc Compuestos y uso de los mismos en la modulacion beta amiloide.
JP5010917B2 (ja) 2003-08-29 2012-08-29 エグゼリクシス， インコーポレイテッド ｃ−Ｋｉｔ調節因子および使用方法
CA2551038C (en) 2003-12-22 2010-04-27 Pfizer Inc. Triazole derivatives as vasopressin antagonists
AU2005214349B2 (en) * 2004-02-12 2011-11-03 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
CA2558026C (en) 2004-03-09 2010-12-14 Merck & Co., Inc. Hiv integrase inhibitors
BRPI0511504A (pt) 2004-05-26 2008-01-22 Eisai R&D Man Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
US20080261952A1 (en) 2004-08-16 2008-10-23 Jason Bloxham Aryl Urea Derivatives for Treating Obesity
ATE458729T1 (de) 2004-10-26 2010-03-15 Eisai R&D Man Co Ltd Amorphe form einer zimtsäureamidverbindung
US20060241038A1 (en) 2005-04-20 2006-10-26 Eisai Co., Ltd. Therapeutic agent for Abeta related disorders
WO2007034282A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
KR20080076907A (ko) 2005-11-18 2008-08-20 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 유도체의 제조 방법
US20090048448A1 (en) 2005-11-18 2009-02-19 Ikuo Kushida Salts of cynnamide compound or solvates thereof
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
US20070117839A1 (en) 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
MY144960A (en) 2005-11-24 2011-11-30 Eisai R&D Man Co Ltd Morpholine type cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
WO2007102580A1 (ja) 2006-03-09 2007-09-13 Eisai R & D Management Co., Ltd. 多環式シンナミド誘導体
SA07280403B1 (ar) 2006-07-28 2010-12-01 إيساي أر أند دي منجمنت كو. ليمتد ملح رباعي لمركب سيناميد
WO2008097538A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
US20080207900A1 (en) 2007-02-28 2008-08-28 Teiji Kimura Two cyclic oxomorphorin derivatives
WO2008137102A2 (en) 2007-05-04 2008-11-13 Torreypines Therapeutics, Inc. Methods of modulating amyloid beta and compounds useful therefor
MX2009012177A (es) 2007-05-07 2009-11-23 Schering Corp Moduladores de gamma-secretasa.
MX2009012163A (es) 2007-05-11 2009-12-01 Hoffmann La Roche Hetarilanilinas como moduladores para beta-amiloide.
EP2166854A4 (en) 2007-06-13 2012-05-16 Merck Sharp & Dohme TRIAZONE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED SUFFERINGS
WO2009020580A1 (en) 2007-08-06 2009-02-12 Schering Corporation Gamma secretase modulators
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
EP2181992B8 (en) 2007-08-31 2013-06-26 Eisai R&D Management Co., Ltd. Polycyclic compound
JP2011506335A (ja) 2007-12-06 2011-03-03 シェーリング コーポレイション γ−セクレターゼ調節剤
WO2009126311A1 (en) * 2008-04-11 2009-10-15 The University Of Texas, M.D. Anderson Cancer Center Radiosensitization of tumors with indazolpyrrolotriazines for radiotherapy
EP2324009A1 (en) 2008-08-27 2011-05-25 Eisai R&D Management Co., Ltd. Process for preparing certain cinnamide compounds
AP2011005808A0 (en) 2009-02-26 2011-08-31 Boehringer Ingelheim Int Compounds as bradykinin B1 antagonists.
WO2010098490A1 (en) 2009-02-26 2010-09-02 Eisai R&D Management Co., Ltd. Salt of tetrahydrotriazolopyridine derivative and crystal thereof
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
EP2401270B1 (en) 2009-02-26 2013-10-16 Glaxo Group Limited Pyrazole derivatives used as ccr4 receptor antagonists
EP2402135A4 (en) 2009-02-27 2014-09-10 Hoya Corp MOLD AND METHOD FOR PRODUCING A LENS OF PLASTIC MATERIAL
ES2519565T3 (es) 2009-07-15 2014-11-07 Janssen Pharmaceuticals Inc. Derivados de triazol e imidazol sustituidos como moduladores de gamma secretasa
US8381014B2 (en) * 2010-05-06 2013-02-19 International Business Machines Corporation Node controller first failure error management for a distributed system

Also Published As

Publication number Publication date
AU2008292390B2 (en) 2013-04-04
EP2181992B1 (en) 2013-05-01
US9453000B2 (en) 2016-09-27
EP2181992A1 (en) 2010-05-05
IL203778A (en) 2013-11-28
EP2559693A1 (en) 2013-02-20
AR068121A1 (es) 2009-11-04
ZA201000474B (en) 2011-05-25
ES2529648T3 (es) 2015-02-24
MX2010002098A (es) 2010-03-30
BRPI0815773A2 (pt) 2019-09-24
NZ583515A (en) 2011-05-27
CA2694401A1 (en) 2009-03-05
EP2559693B1 (en) 2014-11-26
CN101815713B (zh) 2013-09-11
KR20100055456A (ko) 2010-05-26
JP5433418B2 (ja) 2014-03-05
EP2181992B8 (en) 2013-06-26
JPWO2009028588A1 (ja) 2010-12-02
US20110009619A1 (en) 2011-01-13
CA2694401C (en) 2012-12-04
MY150507A (en) 2014-01-30
TW200916469A (en) 2009-04-16
CN101815713A (zh) 2010-08-25
WO2009028588A1 (ja) 2009-03-05
EP2181992A4 (en) 2011-09-14
PE20090674A1 (es) 2009-06-19
AU2008292390A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
CL2008002542A1 (es) Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis.
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
UY30500A1 (es) Compuestos de azabencimidazolilo
UY31189A1 (es) Compuestos heterocíclicos
CR11554A (es) Pirrolo-Pirimidinas y Pirrolo-Piridinas
UY30282A1 (es) Compuestos quimicos
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
CL2012000001A1 (es) Compuestos derivados de heteroarilo-pirazolopirimidina-carboxamida, inhibidores de jak; composicion farmaceutica que los comprende; utiles para el tratamiento de la artritis reumatoide, enfermedad de chron, dermatitis, psoriasis, entre otros.
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
CR20130580A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2
ECSP12011622A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
LT3133070T (lt) Eligliustatas (genz 112638) kaip gliukozilceramido sintazės slopiklis, skirtas naudoti fabri arba gošė ligos gydymo būde, kur būdas apima individualios terapinės dozės priderinimą paciento p-450 metabolizmui
DK2150530T3 (da) Substituerede sulfonamid-derivater
AR060675A1 (es) Derivados de n-(2-tiazolil)-amida como inhibidores de gsk-3,metodo de preparacion, composiciones farmaceuticas que los contienen,y usos terapeuticos.
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
CO6511222A2 (es) Derivado de idenona y composición famacéutica que comprende el mismo
UY31141A1 (es) Compuestos de piperidina y sus usos
DOP2010000317A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
ATE526015T1 (de) Arzneimittel sowie deren herstellung und verwendung bei der behandlung von schmerzhaften neuropathien
ECSP088250A (es) Derivados de pirazol como agentes terapéuticos
ECSP099506A (es) Derivados de 2-quinolinona y 2 quinoxalinona y su utilización como agentes anti bacterianos